Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)

• 1 Royal Prince Alfred Hospital, Sydney, NSW
• 2 Westmead Hospital, Sydney, NSW
• 3 University of Sydney, Sydney, NSW
• 4 Skin and Cancer Foundation Australia, Sydney, NSW

---

• 1. Bourke JM, O’Sullivan M, Khattak MA. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). Med J Aust 2016; 205: 418-424. <MJA full text>
• 2. Hwang SJE, Anforth R, Carlos G, Fernandez-Penas P. Cutaneous adverse events of new anti-melanoma therapies: classification and management. Actas Dermosifiliogr 2017; 108: 6-16.
• 3. Hwang SJ, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of antiprogrammed cell-death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016; 74: 455-461.
• 4. Carlos GRM, Fernandez-Penas P, Uribe P. Rational use of topical corticosteroids. Aust Prescr 2013; 36: 159-161.
• 5. Sebaratnam DF, Murrell DF. Dermatology training and practice in Australia. Int J Dermatol 2014; 53: 1259-1264.